Mylan failed to meet the burden to trigger review of a patent covering Bayer’s drug Xarelto, the Patent Trial and Appeal Board said in a decision on its electronic docket. The board Dec. 3 declined to institute review of the patent, U.S. Patent No. 9,539,218, for a way of treating blood-clot disorder with a once-daily dose of the drug. Mylan claimed the patent didn’t cover a new invention, and filed a petition for review after Bayer and partner Johnson & Johnson sued to prevent Mylan from selling a generic version of the drug. The patent expires in February 2034, according... To read the full article . To learn more about a subscription .
The US Patent Trial and Appeal Board has ruled against Mylan in its attempts to force a patent review of Bayer's blood clot disorder treatment. In the ruling, which was published on Monday, the board said that it had found no evidence that Bayer or any other company had infringed on patents held by Mylan.